<!DOCTYPE html>
<html>
<head>
	<title>Cimzia Detail Aid | Mode of Action</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0">
	<meta name="format-detection" content="telephone=no">
	<link rel="stylesheet" href="css/owl.carousel.css">
	<link rel="stylesheet" href="css/magnific-popup.css">
	<link rel="stylesheet" href="css/style.css">
	<script src="cordova.js"></script>
</head>

<body>
	<!-- svg defs for icons with rollovers states usage <svg><use xlink:href="#ID NAME" /></svg> -->
	<svg style="display: none;">
	<symbol id="rosette" width="49.417px" height="50px" viewBox="0 0 49.417 50" enable-background="new 0 0 49.417 50" xml:space="preserve">
	<polygon points="26.654,0 24.708,1.249 22.764,0 21.036,1.542 18.923,0.615 17.455,2.412 15.224,1.831 14.053,3.839 11.759,3.618
		10.912,5.786 8.613,5.931 8.111,8.206 5.863,8.713 5.719,11.04 3.577,11.897 3.794,14.217 1.811,15.403 2.385,17.661 0.61,19.146
		1.525,21.285 0,23.033 1.237,25 0,26.967 1.525,28.716 0.61,30.854 2.385,32.34 1.811,34.598 3.794,35.782 3.577,38.104
		5.719,38.96 5.863,41.286 8.111,41.794 8.613,44.07 10.912,44.214 11.759,46.382 14.053,46.162 15.224,48.169 17.455,47.588
		18.923,49.384 21.036,48.458 22.764,50 24.708,48.75 26.654,50 28.38,48.458 30.494,49.384 31.962,47.588 34.193,48.169
		35.365,46.162 37.66,46.382 38.505,44.214 40.805,44.07 41.306,41.794 43.554,41.286 43.699,38.96 45.841,38.104 45.623,35.782
		47.606,34.598 47.033,32.34 48.808,30.854 47.893,28.716 49.417,26.967 48.181,25 49.417,23.033 47.893,21.285 48.808,19.146
		47.033,17.661 47.606,15.403 45.623,14.217 45.841,11.897 43.699,11.04 43.554,8.713 41.306,8.206 40.805,5.931 38.505,5.786
		37.66,3.618 35.365,3.839 34.193,1.831 31.962,2.412 30.494,0.615 28.38,1.542 "/>
	</symbol>
	<symbol id="info" width="20px" height="20px" viewBox="0 0 20 20" enable-background="new 0 0 20 20" xml:space="preserve">
	<path d="M10,0C4.477,0,0,4.478,0,10c0,5.523,4.477,10,10,10s10-4.477,10-10C20,4.478,15.523,0,10,0z M10,19.089
		c-5.012,0-9.09-4.077-9.09-9.089S4.988,0.91,10,0.91s9.09,4.078,9.09,9.09S15.012,19.089,10,19.089z M10.949,8.379v7.072
		c0,0.528-0.422,0.949-0.949,0.949s-0.949-0.421-0.949-0.949V8.379C9.051,7.853,9.473,7.43,10,7.43S10.949,7.853,10.949,8.379z
		 M11.16,4.76c0,0.633-0.506,1.16-1.16,1.16c-0.633,0-1.16-0.527-1.16-1.16C8.84,4.128,9.367,3.6,10,3.6
		C10.654,3.6,11.16,4.128,11.16,4.76z"/>
	</symbol>
	<symbol id="references" width="26.482px" height="20px" viewBox="0 0 26.482 20" enable-background="new 0 0 26.482 20" xml:space="preserve">
	<path d="M26.347,3.527c-0.676-0.675-1.408-1.242-2.177-1.684l-0.204-0.118V0.654c0-0.227-0.163-0.419-0.387-0.457
		C22.805,0.067,22.034,0,21.287,0c-4.069,0-6.642,1.882-7.812,3.003l-0.246,0.236l-0.275-0.201c-1.187-0.864-3.609-2.315-6.511-2.315
		c-2.324,0-4.446,0.943-6.308,2.803C0.048,3.614,0,3.731,0,3.854V19.15c0,0.157,0.084,0.308,0.22,0.393
		c0.073,0.045,0.158,0.068,0.245,0.068c0.071,0,0.142-0.016,0.205-0.047c0.021-0.012,2.322-1.135,5.684-1.135
		c2.28,0,4.519,0.508,6.659,1.512l0.033,0.016c0.025,0.012,0.054,0.021,0.101,0.033c0.024,0.004,0.05,0.009,0.073,0.01h0.027
		c0.024-0.001,0.049-0.004,0.074-0.008l0.029-0.004c0.09-0.008,0.172-0.037,0.239-0.088l0.035-0.024l0.04-0.019
		c2.083-0.947,4.258-1.427,6.463-1.427c3.214,0,5.433,1.015,5.685,1.134c0.063,0.032,0.134,0.049,0.206,0.049
		c0.086,0,0.17-0.023,0.244-0.069c0.138-0.086,0.22-0.233,0.22-0.394V3.855C26.482,3.733,26.433,3.613,26.347,3.527z M12.776,18.81
		l-0.553-0.212c-1.897-0.727-3.873-1.096-5.87-1.096c-2.117,0-3.829,0.415-4.893,0.762l-0.534,0.174V4.047l0.129-0.121
		c1.615-1.509,3.427-2.275,5.387-2.275c2.854,0,5.269,1.606,6.175,2.297l0.159,0.122V18.81z M13.777,18.371V4.017l0.112-0.118
		c0.666-0.697,3.169-2.971,7.397-2.971c0.454,0,0.921,0.026,1.39,0.079l0.362,0.04V15.39l-0.442-0.036
		c-0.303-0.025-0.615-0.039-0.927-0.039c-1.51,0-4.459,0.329-7.232,2.531L13.777,18.371z M25.556,18.438l-0.534-0.174
		c-1.063-0.347-2.775-0.761-4.893-0.761c-0.56,0-1.144,0.032-1.736,0.097c-1.427,0.096-2.576,0.508-3.627,0.96
		c1.585-1.343,3.452-1.751,3.452-1.751c1.106-0.376,2.268-0.566,3.452-0.566c0.948,0,1.593,0.129,1.687,0.15l0.037,0.008
		c0.035,0.008,0.072,0.012,0.108,0.012c0.104,0,0.206-0.035,0.287-0.098c0.111-0.09,0.177-0.223,0.177-0.365V2.595l0.68,0.614
		c0.265,0.238,0.526,0.479,0.78,0.717l0.13,0.121V18.438z"/>
	</symbol>
	</svg>
<div class="overflow_wrapper">
	<div class="main_menu">
		<div class="main_menu_inner">
			<a href="index.html" class="home">Home</a>
			<ul class="tabs">
				<li class="tab" data-menuid="#ra">
					<svg><use xlink:href="#rosette"/></svg>
					<span>RA</span>
				</li>
				<li class="tab" data-menuid="#as">
					<svg><use xlink:href="#rosette"/></svg>
					<span>AS</span>
				</li>
				<li class="tab last active" data-menuid="#psa">
					<svg><use xlink:href="#rosette"/></svg>
					<span>PsA</span>
				</li>
			</ul>
			<ul class="menu" id="ra">
				<li><a href="ra-story.html">Ellen's Story</a></li>
				<li>
					<span class="has_ul">RA Details</span>
					<ul>
						<li><a href="ra-study.html">REALISTIC Study</a></li>
						<li><a href="ra-longterm.html">Long-Term Data</a></li>
						<li><a href="ra-loading.html">Loading Dose</a></li>
					</ul>
				<li><a href="ra-tolerability.html">Tolerability</a></li>
				<li><a href="ra-usage.html">Usage</a></li>
				<li><a href="ra-mode.html">Mode of Action</a></li>
				<li><a href="ra-esp.html">Everyday Support Program</a></li>
				<li><a href="ra-abbreviations.html">Abbreviations</a></li>
				</li>
			</ul>
			<ul class="menu" id="as">
				<li><a href="as-story.html">Ben's Story</a></li>
				<li>
					<span class="has_ul">AS Details</span>
					<ul>
						<li><a href="as-study.html">RAPID-axSpA Study</a></li>
						<li><a href="as-longterm.html">Long-Term Data</a></li>
						<li><a href="as-loading.html">Loading Dose</a></li>
					</ul>
				</li>
				<li><a href="as-tolerability.html">Tolerability</a></li>
				<li><a href="as-usage.html">Usage</a></li>
				<li><a href="as-mode.html">Mode of Action</a></li>
				<li><a href="as-esp.html">Everyday Support Program</a></li>
				<li><a href="as-abbreviations.html">Abbreviations</a></li>
			</ul>
			<ul class="menu open" id="psa">
				<li><a href="psa-story.html">Sophia's Story</a></li>
				<li>
					<span class="has_ul">PsA Details</span>
					<ul>
						<li><a href="psa-study.html">RAPID-PsA Study</a></li>
						<li><a href="psa-longterm.html">Long-Term Data</a></li>
						<li><a href="psa-loading.html">Loading Dose</a></li>
					</ul>
				</li>
				<li><a href="psa-tolerability.html">Tolerability</a></li>
				<li><a href="psa-usage.html">Usage</a></li>
				<li class="active">Mode of Action</li>
				<li><a href="psa-esp.html">Everyday Support Program</a></li>
				<li><a href="psa-abbreviations.html">Abbreviations</a></li>
			</ul>
		</div>
	</div>

	<div class="content_wrap mode story">
		<header>
		<a href="#" id="menu_toggle" class="menu_toggle">Menu</a>
		<a href="index.html"><img id="logo" src="images/logo.svg"></a>
		</header>
		<div class="owl-carousel">

			<!--Point 1-->
			<div class="item">
				<div class="two_cols">
					<div class="col_1">
						<h2 class="headline starburst_orange"><span class="glowing_green">Cimzia<sup>&reg</sup> is designed</span><br>to be different to<br>other anti-TNFs<sup>#1-7</sup></h2>
						<div class="body_copy starburst_orange">
							<p><sup>#</sup>Cimzia<sup>&reg</sup>is the only PEGylated<br>and Fc-free anti-TNF<sup>1-7</sup></p>
						</div>
					</div>
					<div class="image_box col_2" style="background: #fff;">
						<img src="images/backgrounds/mode-PEGylated-preview.jpg">
						<a href="#tolerability-1" class="open-popup-link magnify">
							<img src="images/icons/magnify-grey.svg">
						</a>
						<div id="tolerability-1" class="popup_container no_header mfp-hide">
							<div class="graph_wrap" style="background: transparent;">
								<img src="images/backgrounds/mode-PEGylated.jpg">
							</div>
							<div class="reference_text_wrap">
								<div class="reference_text">
									<div class="white">
										<p><strong>References</strong></p>
										<p>1. Ferrante M, Vermeire S, Rutgeerts PJ. Expert Opin Drug Saf 2014; 13 (2): 255-266.</p>
										<a class="clear_button" onclick="window.open('downloads/Ferrante-ExpertOpinDrugSaf-2014.pdf', '_blank', 'location=no');">Ref.1 Full Paper (PDF)</a>
										<p>2. Tracey D, Klareskog L, Sasso EH et al. Pharmacol Ther 2008; 117 (2): 244-279.</p>
										<a class="clear_button" onclick="window.open('downloads/Tracey-PharmacolTher-2008.pdf', '_blank', 'location=no');">Ref.2 Full Paper (PDF)</a>
										<p>3. Cimzia<sup>&reg</sup> Approved Product Information, May 2014.</p>
										<a class="clear_button" onclick="window.open('downloads/PI-CMI.pdf', '_blank', 'location=no');">Ref.3 Full Paper (PDF)</a>
										<p>4. Enbrel<sup>&reg</sup> Approved Product Information, August 2013.</p>
										<p>5. Humira<sup>&reg</sup> Approved Product Information, November 2013.</p>
										<p>6. Simponi<sup>&reg</sup> Approved Product Information, August 2013.</p>
										<p>7. Remicade<sup>&reg</sup> Approved Product Information, December 2013.</p>
										<p>8. Mahadevan U, Wolf DC, Dubinski M et al. Clin Gastroenterol Hepatol 2013; 11 (3): 286-292.</p>
										<a class="clear_button" onclick="window.open('downloads/Mahadevan-ClinGastroenterolHepatol-2013.pdf', '_blank', 'location=no');">Ref.8 Full Paper (PDF)</a>
									</div>
								</div>
							</div>
							<!-- close button added via js -->
							<a href="#" class="open_references open_refs_icon"><svg><use xlink:href="#references" /></svg></a>
						</div>
					</div>
				</div>
				<div class="slide_references">
					<img class="close_popup" src="images/icons/close-popup.svg">
					<div class="center_outer">
						<div class="center_inner">
							<h4 class="text_breakout starburst_orange">References & Abbreviations</h4>
							<div class="references_and_abbreviations_text">
								References: <strong>1.</strong> Ferrante M, Vermeire S, Rutgeerts PJ. Expert Opin Drug Saf 2014; 13 (2): 255-266. <strong>2.</strong> Tracey D, Klareskog L, Sasso EH et al. Pharmacol Ther 2008; 117 (2): 244-279. <strong>3.</strong> Cimzia<sup>&reg</sup> Approved Product Information, May 2014. <strong>4.</strong> Enbrel<sup>&reg</sup> Approved Product Information, August 2013. <strong>5.</strong> Humira<sup>&reg</sup> Approved Product Information, November 2013. <strong>6.</strong> Simponi<sup>&reg</sup> Approved Product Information, August 2013. <strong>7.</strong> Remicade<sup>&reg</sup> Approved Product Information, December 2013. <strong>8.</strong> Mahadevan U, Wolf DC, Dubinski M et al. Clin Gastroenterol Hepatol 2013; 11 (3): 286-292.
								<br><br>
								<strong>ACR20/ACR50/ACR70:</strong> American College of Rheumatology 20%/50%/70% Improvement.
								<strong>AS:</strong> Ankylosing Spondylitis.
								<strong>ASAS20/40:</strong> Assessment of SpondyloArthritis international Society 20%/40% Improvement.
								<strong>axSpA:</strong> Axial Spondyloarthritis.
								<strong>BASDAI:</strong> Bath Ankylosing Spondylitis Disease Activity Index.
								<strong>BASFI:</strong> Bath Ankylosing Spondylitis Functional Index.
								<strong>CRP:</strong> C-Reactive Protein
								<strong>CZP:</strong> Certolizumab pegol (Cimzia<sup>&reg;</sup>)
								<strong>CDAI:</strong> Clinical Disease Activity Index.
								<strong>DAS28:</strong> Low Disease Activity Score.
								<strong>DMARD:</strong> Disease Modifying Anti-Rheumatic Drug.
								<strong>ESR:</strong> Erythrocyte Sedimentation Rate
								<strong>FAS:</strong> Fatigue Analogue Scale.
								<strong>HAQ-DI:</strong> Health Assessment Questionnaire-Disability Index.
								<strong>ITT:</strong> Intention-To-Treat
								<strong>MACE:</strong> Major Adverse Cardiac Events.
								<strong>MCID:</strong> Minimal Clinically Important Difference.
								<strong>mTSS:</strong> modified Total Sharp Score.
								<strong>MTX:</strong> Methotrexate.
								<strong>NSAID:</strong> Non-Steroidal Anti-Inflammatory Drug.
								<strong>OLE:</strong> Open Label Extension.
								<strong>Q2W:</strong> Every 2 weeks.
								<strong>Q4W:</strong> Every 4 weeks.
								<strong>PASI50/75/90:</strong> Psoriasis Area and Severity Index 50%/75%/90% Reduction.
								<strong>PsA:</strong> Psoriatic Arthritis.
								<strong>RA:</strong> Rheumatoid Arthritis.
								<strong>SD:</strong> Standard Deviation
								<strong>SJC:</strong> Swollen Joint Count.
								<strong>TJC:</strong> Tender Joint Count.
								<strong>TNF:</strong> Tumour Necrosis Factor.
								<strong>WPS-RA:</strong> RA-specific Work Productivity Survey.
							</div>
						</div>
					</div>
				</div>

			</div>

			<!--Point 2-->
			<div class="item">
				<h2 class="headline starburst_orange mode_heading"><span class="glowing_green">Cimzia<sup>&reg</sup><br>Mode of Action</span><br>Videos</h2>
				<div class="cols_wrap">
					<div class="colspan_3" style="background: #fff;">
						<img src="images/videos/mode-video-1-preview.svg">
						<!-- POPUP *href need to have the id of the popup -->
						<a href="#video_1" class="open-popup-link magnify">
							<img src="images/icons/play-grey.svg">
						</a>
						<div id="video_1" class="popup_container mfp-hide">
							<div class="graph_wrap">
								<video controls>
									<source src="video/mode-introduction.mp4" type="video/mp4">
								</video>
							</div>
						</div>
					</div>
					<div class="colspan_3" style="background: #fff;">
						<img src="images/videos/mode-video-2-preview.svg">
						<!-- POPUP *href need to have the id of the popup -->
						<a href="#video_2" class="open-popup-link magnify">
							<img src="images/icons/play-grey.svg">
						</a>
						<div id="video_2" class="popup_container mfp-hide">
							<div class="graph_wrap">
								<video controls>
									<source src="video/mode-monovalent.mp4" type="video/mp4">
								</video>
							</div>
						</div>
					</div>
					<div class="colspan_3" style="background: #fff;">
						<img src="images/videos/mode-video-3-preview.svg">
						<!-- POPUP *href need to have the id of the popup -->
						<a href="#video_3" class="open-popup-link magnify">
							<img src="images/icons/play-grey.svg">
						</a>
						<div id="video_3" class="popup_container mfp-hide">
							<div class="graph_wrap">
								<video controls>
									<source src="video/mode-PEGylation.mp4" type="video/mp4">
								</video>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>

		<!--minimum PI-->
		<div id="info">
			<div class="center_outer">
				<div class="center_inner">
					<img class="close_popup" src="images/icons/close-popup.svg">
					<div class="info_content dark_grey">
						<div class="pbs_box">
						<strong>PBS Information:</strong> Authority required for the treatment of severe active rheumatoid arthritis and severe active ankylosing spondylitis. Not PBS listed for the treatment of psoriatic arthritis. Refer to PBS Schedule for full Authority information.
						</div>
						<h2>Before prescribing, please review the Product Information<br>available from UCB Australia or <a class="mandatories_link" onclick="window.open('https://www.ebs.tga.gov.au/', '_blank', 'location=no');">https://www.ebs.tga.gov.au/</a><br><a class="white_button" onclick="window.open('downloads/PI-CMI.pdf', '_blank', 'location=no');">Read Full PI (PDF)</a></h2>
						<p><strong>Cimzia<sup>&reg</sup></strong> (certolizumab pegol) 200mg/mL prefilled syringe. <strong>Minimum Product Information. Approved Indication:</strong> Rheumatoid Arthritis: Cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients: combined with methotrexate (MTX) in case of either an inadequate response or intolerance to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) or as monotherapy in case of a contraindication or intolerance to MTX. Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when given in combination with MTX. Psoriatic Arthritis: Cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous DMARDs has been inadequate. Cimzia has been shown to improve physical function. Ankylosing Spondylitis: Cimzia is indicated for the treatment of adult patients with active ankylosing spondylitis who have been intolerant to or have inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID). <strong>Dosage and Method of Use:</strong> Recommended dose 400mg (2 x 200mg subcutaneous injections) at weeks 0, 2 and 4, followed by a maintenance dose of 200mg every 2 weeks via subcutaneous injection. Alternatively, when a maintenance dose of 200mg every 2 weeks is not practical, a maintenance dose of 400mg every 4 weeks can be considered. <strong>Contraindications:</strong> Hypersensitivity to any components of the product. Active tuberculosis (TB) or other severe infections. Concurrent administration with anakinra. Moderate to severe heart failure (NYHA classes III/IV). <strong>Precautions:</strong> Monitor for symptoms of malignancy and lymphoproliferative disorders, infections, including Hepatitis B Virus, skin cancers, latent TB (see full PI); chronic obstructive pulmonary disease and risk of malignancy due to heavy smoking); congestive heart failure (CHF); new/worsening CHF (discontinue); exercise caution in patients who have ongoing, or history of significant haematologic abnormalities; demyelinating disorders; concurrent administration with other biological response modifier; psoriasis &ndash; new-onset and exacerbations; elderly; pregnancy (Category C), lactation, children. <strong>Adverse Effects:</strong> Bacterial infections, viral infections, eosinophilic disorders, leukopaenia, headaches, sensory abnormalities, hypertension, nausea, hepatitis, rash, pyrexia, pain, asthaenia, pruritus, injection site reactions; more details see full PI. Based on the full disclosure Product Information. Date of first inclusion in the ARTG 20 January 2010. Date of most recent amendment 29th January 2015.</p><br>
						<p>UCB Australia Pty Ltd, ABN 48 005 799 208, Level 1, 1155 Malvern Road, Malvern, VIC 3144. Telephone (03) 9828 1800. Facsimile (03) 9828 1860. Cimzia<sup>&reg</sup> is a registered trademark of UCB Pharma, S.A. Date of preparation: February 2015. PC CODE: 1404 CIM21</p>
						<img class="oxo_logo" src="images/oxo-logo.svg">
						<p>OXO<sup>&reg;</sup>, Good Grips<sup>&reg;</sup> and the associated logos are registered trademarks of Helen of Troy Limited and are used under license.</p>
						<img class="ucb_logo" src="images/ucb-logo.svg">
					</div>
				</div>
			</div>
		</div>

		<!--footer-->
		<footer>
			<h6 class="section_title">Mode of Action</h6>
			<div class="carousel_nav">
			</div>
			<div class="info_ref">
				<a href="#" id="open_ref"><svg><use xlink:href="#references" /></svg></a>
				<a href="#" id="open_info"><svg><use xlink:href="#info" /></svg></a>
			</div>
		</footer>
	</div>
</div>
</body>

<script src="js/lib/jquery-1.11.2.min.js"></script>
<script src="js/lib/owl.carousel.min.js"></script>
<script src="js/lib/jquery.magnific-popup.min.js"></script>
<script src="js/js.js"></script>
</html>